Fortress Biotech Inc (FBIO)

Fortress Biotech, Inc. is a biopharmaceutical company listed on NASDAQ under the ticker FBIO. As a common equity security, it represents an ownership interest in the company rather than a fund or other special instrument. Fortress Biotech focuses on the development and commercialization of biopharmaceutical products across a broad range of therapeutic areas. Its marketed portfolio includes dermatology and related treatments such as Emrosi, Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. The company also advances a pipeline that includes intravenous Tramadol, CUTX-101, UNLOXCYT, Olafertinib, CAEL-101, and Triplex, along with early-stage and preclinical candidates spanning oncology, neurology, rare disease, immunology, and gene therapy. Formerly known as Coronado Biosciences, Inc., the company adopted its current name in 2015 and is based in Bay Harbor Islands, Florida.

Jump directly to the stock analysis sections supported by the latest available data.